Bladder Cancer Drug That Received Accelerated Approval Shows Even Stronger Findings in Later Study

According to a publication from Medscape, the first ever drug targeted for bladder cancer has shown even more impressive results in post-approval study. Erdafitinib was approved on an accelerated basis…

Continue Reading Bladder Cancer Drug That Received Accelerated Approval Shows Even Stronger Findings in Later Study
Estela Lugo of the Hereditary Neuropathy Foundation Seeks to Raise Charcot-Marie-Tooth Disease Awareness
harpenz / Pixabay

Estela Lugo of the Hereditary Neuropathy Foundation Seeks to Raise Charcot-Marie-Tooth Disease Awareness

According to a story from Charcot-Marie-Tooth Disease News, Charcot-Marie-Tooth disease is actually somewhat common in the US compared to other rare diseases. In fact, it is estimated that around 150,000…

Continue Reading Estela Lugo of the Hereditary Neuropathy Foundation Seeks to Raise Charcot-Marie-Tooth Disease Awareness
Immunocore and Pulse Infoframe Lend Support to International Uveal Melanoma Patient Registry
Source: Pixabay

Immunocore and Pulse Infoframe Lend Support to International Uveal Melanoma Patient Registry

According to a press release from British biotechnology company Immunocore, the Company has partnered with Pulse Infoframe (a Canadian data analytics company) to support the development of an international database…

Continue Reading Immunocore and Pulse Infoframe Lend Support to International Uveal Melanoma Patient Registry
Researchers Discover “Testicular Cancer-Associated Paraneoplastic Encephalitis,” an Autoimmune Disease
derneuemann / Pixabay

Researchers Discover “Testicular Cancer-Associated Paraneoplastic Encephalitis,” an Autoimmune Disease

According to a story from Cancer Health, a team of scientists affiliated with Mayo Clinic, UC San Francisco, and the Chan Zuckerburg Biohub have discovered a new rare, autoimmune disease…

Continue Reading Researchers Discover “Testicular Cancer-Associated Paraneoplastic Encephalitis,” an Autoimmune Disease
Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows
cherylholt / Pixabay

Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows

According to a story from Angioedema News, a recent clinical trial has demonstrated that the drug conestat alfa (marketed as Ruconest) was able to successfully treat 96 percent of acute…

Continue Reading Hereditary Angioedema Drug Shows Safety and Efficacy in Pediatric Patients, Study Shows

Study Findings Result in New Diagnostic Recommendations for Hereditary Angioedema in the ER

According to a story from Angioedema News, a team of researchers has used data from a recent study to provide up to date recommendations for diagnosing hereditary angioedema in the…

Continue Reading Study Findings Result in New Diagnostic Recommendations for Hereditary Angioedema in the ER
Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters
https://pixabay.com/en/sunset-sun-sisters-girl-shadow-929179/

Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

An article from Comic Sands recently covered the story of a UK mother, Alison Beesley, who is now committed to taking care of her daughters Eliza and Eleanor full time. Eliza is nine years old and…

Continue Reading Scleroderma: The Skin-Hardening Disease Affecting Two UK Sisters

Experimental Treatment for Acute Myeloid Leukemia Earns Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Mustang Bio, Inc. has recently announced that the US Food and Drug Administration (FDA) has recently awarded the company Orphan Drug…

Continue Reading Experimental Treatment for Acute Myeloid Leukemia Earns Orphan Drug Designation
New Biosimilar to Rituxan Earns FDA Approval
source: pixabay.com

New Biosimilar to Rituxan Earns FDA Approval

According to a story from drugs.com, the pharmaceutical company Pfizer, Inc. recently issued an announcement detailing the approval of its drug Ruxience (rituximab-pvvr), a biosimilar to the widely used monoclonal…

Continue Reading New Biosimilar to Rituxan Earns FDA Approval
Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy
luvqs / Pixabay

Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy

According to a press release from the Kentucky-based Apellis Pharmaceuticals, the Company has initiated a program to investigate the use of APL-9, an investigational drug, in gene therapies that involve…

Continue Reading Apellis Pharmaceuticals Launches Program Investigating Potential of APL-9 for Preventing AAV Resistance in Gene Therapy
India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
klbz / Pixabay

India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases

According to a story from health.economictimes.indiatimes.com, the country of India is currently beginning to take more steps in order to address the dire unmet medical need of its rare disease…

Continue Reading India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
source: pixabay.com

Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders

According to a press release from Takeda Pharmaceutical Company published by For Press Release, the Company has launched a collection of enzyme replacement therapies for use in the treatment of…

Continue Reading Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center
Source: Pixabay

First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center

According to a publication from Charcot-Marie-Tooth News, the first patient has been enrolled in the first ever natural history study of type 4J Charcot-Marie-Tooth disease. Study collaborators — biotechnology company…

Continue Reading First-of-its-Kind Study of Charcot-Marie-Tooth Disease Type 4J to Begin at UT Southwestern Med Center